RaySearch Laboratories AB (publ) Year-end Report for 2008

RaySearch Laboratories AB (publ) Year-end Report for 2008

JANUARY 1 - DECEMBER 31, 2008 
•	Net sales for the period totaled SEK 62.7 M (64.7) 
•	Profit after tax was SEK 18.2 M (19.8) 
•	Earnings per share amounted to SEK 0.53 (0.58) 
•	Operating profit was SEK 21.1 M (25.8)
•	Cash flow from operating activities totaled SEK 26.0 M (37.9)
•	An agreement with Philips covering a product for the new treatment method VMAT
was reached in June
•	A cooperation agreement covering research within multi-criteria optimization
with Massachusetts General Hospital in Boston, U.S., was signed in August
•	The first patient was treated using RaySearch's system for proton therapy in
December 
•	The Board proposes that no dividend be paid 

AFTER THE CLOSE OF THE PERIOD 
•	The collaboration with Nucletron was extended in January with two new
solutions for treatment planning 
•	The first product from the collaboration with TomoTherapy received FDA
clearance in January and can therefore be launched

“It is highly pleasing that 2008 ended with the highest quarterly revenues in
RaySearch's history. As a result, nearly the entire sales dip in the sluggish
second and third quarters was offset,” comments Johan Löf, President and CEO of
RaySearch.

“2009 will be a record year in terms of new products, with market launches by
all our five partners. The number of revenue-generating products is therefore
expected to almost double during the year,” concludes Johan Löf.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

ABOUT RAYSEARCH
RaySearch Laboratories is a medical-technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners such as
Philips, Varian, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have
been released to date and RaySearch's software is used at over 1,300 clinics in
more than 30 countries. In addition, existing license agreements cover more than
15 other products that are scheduled to be launched in the coming years.
RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in
Stockholm and the company is listed in the Small Cap segment on the OMX Nordic
Exchange Stockholm. 

For more information about RaySearch, visit www.raysearchlabs.com.